ClinicalTrials.gg
CompletedNCT04889430APPELHUSUpdated Aug 7, 2026

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

A Phase 3 interventional study of Iptacopan in Atypical Hemolytic Uremic Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 36 sites in 8 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States — 3 open to participants now, 5 under way, 2 of them phase 3. Atypical Hemolytic Uremic Syndrome · United States.

Enrollment
6th of 13
34 · median 34
Started
2022
the only one that year
Phase 3
6 of 20
none open now
Registered
17th of 20
by date
Lead sponsor
1 of 20
Novartis Pharmaceuticals

Among the 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2022, is one of 6 in phase 3, and was the 17th registered.

Atypical Hemolytic Uremic Syndrome

45 studies on the registry are indexed under Atypical Hemolytic Uremic Syndrome; 14 are open to participants now.

Browse Atypical Hemolytic Uremic Syndrome studies →

Open to participants now

3 of the 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Atypical Hemolytic Uremic Syndrome studies recruiting now, 10 (83%) set no upper age limit and none (0%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.

Read the detailed description

The study is designed as a multicenter, single-arm, open label study to demonstrate the efficacy and safety of LNP023 (iptacopan) at a dose of 200 mg b.i.d. in adult patients with aHUS who are treatment naive to complement inhibitor therapy (including anti-C5 antibody). The study will enroll approximately 50 participants and assess the effects of iptacopan on a range of efficacy assessments relevant to aHUS including hematological and kidney parameters, dialysis requirement, changes in chronic kidney disease (CKD) stage, as well as patient reported outcomes (PRO) for fatigue and quality of life.

03

Conditions studied

  • Atypical Hemolytic Uremic Syndrome

Keywords

  • LNP023
  • iptacopan
  • aHUS
  • atypical hemolytic uremic syndrome
  • thrombotic microangiopathy
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Adult patients with evidence of active thrombotic microangiopathy (TMA), including thrombocytopenia, evidence of hemolysis, and acute kidney injury
  • Vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections are required prior to the start of study treatment. If the patient has not been previously vaccinated, or if a booster is required, vaccine should be given according to local regulations, at least 2 weeks prior to first study drug administration. If study treatment has to start earlier than 2 weeks post vaccination or before vaccination is given, prophylactic antibiotic treatment must be administered at the start of study treatment and for at least 2 weeks after vaccination

Main Exclusion Criteria:

  • Treatment with complement inhibitors, including anti-C5 antibody
  • ADAMTS13 deficiency (\<10% activity or \<0.1U/ml), and/or Shiga toxin-related hemolytic uremic syndrome (STx-HUS), and/or Positive direct Coombs test
  • Identified drug exposure-related HUS or HUS related to known genetic defects of cobalamin C metabolism or known diacylglycerol kinase ε (DGKE) mediated aHUS
  • Receiving PE/PI, for 14 days or longer, prior to the start of screening for the current TMA
  • Bone marrow transplantation (BMT)/hematopoietic stem cell transplantation (), heart, lung, small bowel, pancreas, or liver transplantation
  • Patients with sepsis or active severe systemic bacterial, viral (including COVID-19) or fungal infection, systemic infection which confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease, active infection (or history of recurrent invasive infections) caused by encapsulated bacteria
  • Kidney disease suggestive of other disease than aHUS or of chronic kidney failure or family history of non-complement mediated genetic kidney disease
  • Liver disease or liver injury at screening
  • Systemic sclerosis (scleroderma), systemic lupus erythematosus (SLE), or antiphospholipid antibody positivity or syndrome
  • Chronic hemo- or peritoneal dialysis

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Iptacopan 200 mg b.i.d

    Single arm open-label with 50 adult patients receiving 200mg oral twice daily doses of iptacopan

    Drug: Iptacopan

Interventions

  • Iptacopan 200mg twice daily oral

    Also known as: LNP023

06

What researchers measure

Primary outcomes

  1. Percentage of participants with complete TMA response without the use of PE/PI and anti-C5 antibody

    The number/percentage of participants treated with iptacopan achieving complete thrombotic microangiopathy (TMA) response during 26 weeks of study treatment. Complete TMA Response is defined as (1) hematological normalization in platelet count (platelet count ≥150 x 10\^9/L) and LDH (below ULN), and (2) improvement in kidney function (≥ 25% serum creatinine reduction from baseline), maintained for two measurements obtained at least four weeks apart, and any measurement in between

    Time frame: 26 weeks of study treatment

  2. Long term safety and efficacy evaluations

    Long term (one year) safety, tolerability and efficacy of iptacopan via 1) safety evaluations including adverse events/serious adverse events, safety laboratory parameters, vital signs etc. after 52 weeks of study treatment, and 2) efficacy evaluations including complete TMA response, hematological parameters (platelets, LDH, hemoglobin), eGFR, PROs after 52 weeks of study treatment

    Time frame: 52 weeks of study treatment

Secondary outcomes

  1. Time to achieve complete TMA response

    Effect of study treatment iptacopan on time to complete TMA response during the first 26 weeks of study treatment

    Time frame: 26 weeks of study treatment

  2. Percentage of participants with increase from baseline in hemoglobin levels ≥ 2 g/dL

    Response is defined as the percentage of participants with an increase in hemoglobin of ≥ 2 g/dL from baseline, observed at two measurements obtained at least 4 weeks apart and any measurement in between during 26 weeks of study treatment

    Time frame: 26 weeks of study treatment

  3. Change from baseline on hematologic parameters

    Change from baseline in hematologic parameters (platelets, LDH, hemoglobin) at Week 26

    Time frame: At week 26

  4. Percentage of participants on dialysis

    For participants requiring dialysis within 5 days prior to iptacopan treatment initiation, the number of participants who no longer require dialysis through 26 weeks of study treatment will be evaluated by means of proportion and corresponding confidence interval

    Time frame: 26 weeks of study treatment

  5. Change from baseline on estimated glomerular filtration rate

    Change from baseline in eGFR after 26 weeks of study treatment.

    Time frame: At week 26

  6. Change from baseline in chronic kidney disease (CKD) stage

    Change from baseline in CKD stage (1-5) based on eGFR categories at Week 26

    Time frame: At week 26

  7. Change from baseline in patient-reported outcomes score as measured by the Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Questionnaire

    Change from baseline in patient-reported outcomes scores for FACIT-Fatigue Questionnaire at Week 26

    Time frame: At week 26

  8. Change from baseline in patient-reported outcomes score as measured by the EuroQol 5-level EQ-5D version (EQ-5D-5L) Questionnaire

    Change from baseline in patient-reported outcomes scores for the EuroQol 5-level EQ-5D version (EQ-5D-5L) Questionnaire at Week 26

    Time frame: At Week 26

  9. Change from baseline in patient-reported outcomes score as measured by the Patient Global Impression of Severity (PGIS) questionnaire

    Change from baseline in patient-reported outcomes scores for Patient Global Impression of Severity (PGIS) at Week 26

    Time frame: At Week 26

  10. Change from baseline in patient-reported outcomes score as measured by the Short-form 36 health survey questionnaire version 2 (SF-36 v2)

    Change from baseline in patient-reported outcomes scores for Short-form 36 health survey questionnaire version 2 (SF-36 v2) at Week 26

    Time frame: At Week 26

07

Study locations

36 sites
  • USC Norris Cancer Center
    Los Angeles, California 90033, United States
  • Univ of California at Los Angeles
    Los Angeles, California 90095, United States
  • Univ Cali Irvine ALS Neuromuscular
    Orange, California 92868, United States
  • Univ of California at Sacramento
    Sacramento, California 95817, United States
  • Harbor-UCLA Medical Center .
    Torrance, California 90502, United States
  • Georgetown University Lombardi Cancer Center
    Washington D.C., District of Columbia 20007-2197, United States
  • University Of Miami
    Miami, Florida 33136, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Montefiore Medical Center .
    The Bronx, New York 10461, United States
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267-0585, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Comprehensive Transplant Ctr at OSU
    Columbus, Ohio 43210, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Novartis Investigative Site
    Fortaleza, Ceará 60430 370, Brazil
  • Novartis Investigative Site
    Brasília, Federal District 71635-580, Brazil
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Novartis Investigative Site
    Recife, Pernambuco 50740-900, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90035-074, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 01327 001, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 04038-002, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 05403 000, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, 22270-060, Brazil
  • Novartis Investigative Site
    Salvador, 40323-010, Brazil
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Ostrava, Poruba 708 52, Czechia
  • Novartis Investigative Site
    Nagpur, Maharashtra 440015, India
  • Novartis Investigative Site
    Pune, Maharashtra 411011, India
  • Novartis Investigative Site
    Chandigarh, Punjab 160012, India
  • Novartis Investigative Site
    Lucknow, Uttar Pradesh 226014, India
  • Novartis Investigative Site
    Iruma-gun, Saitama 3500495, Japan
  • Novartis Investigative Site
    Seoul, Seoul 03080, South Korea
  • Novartis Investigative Site
    Taichung, 40447, Taiwan
  • Novartis Investigative Site
    Taoyuan, 33305, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient level data and supporting clinical documents from eligible studies. these requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Apr 2026, 50 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2021
First posted
May 17, 2021
StartActual
Jan 17, 2022
Primary completionActual
Apr 11, 2026
CompletionActual
Apr 11, 2026
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04889430
Responsible party
Sponsor
First posted
May 17, 2021
Start date
Jan 17, 2022
Primary completion
Apr 11, 2026
Completion
Apr 11, 2026
Last update
Aug 7, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iptacopan

Start the discussion